logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Trends & Strategies
  • Life Science & Technology Weekly 141 – Refuge Biotechnologies Raises $25 Million With Support from Chinese Investors

Life Science & Technology Weekly 141 – Refuge Biotechnologies Raises $25 Million With Support from Chinese Investors

Life Science and Tech News Weekly - www.nai500.com
Published on: May 3, 2018
Author: Editor
  • Share article:

Check www.nai500.com for more investment opportunities

Click here to find more details

Suggested Opportunity

RepliCel Life Sciences Inc

RepliCel Life Sciences Inc (TSXV:RP)

RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.

This is NAI’s new Life Science and Technology Weekly. We will be covering the latest news in life science, pharmaceutical, biotech and technology sectors every week. To continue to receive NAI’s Life Science and Technology Weekly, please click Here to subscribe.

Biotechnology Blockchain Electric Cars Healthcare Services Life Science Technology

Related Posts

星链性能再提高,SpaceX达成重要合作

Elon Musk Backs Nvidia, SpaceX Will Exclusively Adopt Its GPUs

穿越低谷:Moderna的创新管线能否照亮前路

Moderna Stock Soars as New Cancer Research Initiative Ignites Market Enthusiasm

人工智能热潮背后的隐形冠军居然是这家公司

AI Compute Demand Remains Strong, Semiconductor Sector Still Bullish on Wall Street During Earnings Season

Bristol Myers Squibb's Zenbexus Posts Win in Phase 3 Trial, What It Means for Investors

Bristol Myers Squibb’s Zenbexus Posts Win in Phase 3 Trial, What It Means for Investors

Nvidia-Backed Lumentum Sees Opto Parts Sold Out to 2029, Hurlston Says

Nvidia-Backed Lumentum Sees Opto Parts Sold Out to 2029, Hurlston Says

信贷市场疲软之际,380亿美元数据中心融资将成AI开支热潮关键试金石

S&P 500 Bull Market Reaches Fourth Anniversary, and History Shows Old Age Is Not Necessarily a Warning

Related News

Elon Musk Backs Nvidia, SpaceX Will Exclusively Adopt Its GPUs

3 hours ago.

Moderna Stock Soars as New Cancer Research Initiative Ignites Market Enthusiasm

4 hours ago.

AI Compute Demand Remains Strong, Semiconductor Sector Still Bullish on Wall Street During Earnings Season

7 hours ago.

Bristol Myers Squibb’s Zenbexus Posts Win in Phase 3 Trial, What It Means for Investors

10 hours ago.

Top Stories

Nvidia-Backed Lumentum Sees Opto Parts Sold Out to 2029, Hurlston Says
Technology

Nvidia-Backed Lumentum Sees Opto Parts Sold Out to 2029, Hurlston Says

人工智能热潮背后的隐形冠军居然是这家公司
Technology

AI Compute Demand Remains Strong, Semiconductor Sector Still Bullish on Wall Street During Earnings Season

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada